Alnylam Pharmaceuticals Continues Onpattro Launch With More to Come
Additional drug approvals and launches are on the way.
Alnylam Pharmaceuticals
ALNY
ALNY
$69.37
$1.46
0.0%
BATS BZX Real Time Price as of May 24, 2019, 3:36 p.m.
View Interactive ALNY Charts
A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.
News & Analysis: Alnylam Pharmaceuticals
The Fool has written over 200 articles on Alnylam Pharmaceuticals.
All
Market Moves
Podcasts
Earnings
Can Alnylam Pharmaceuticals Stock Start Climbing Again?
Investors are starting to wonder if there's anything that can lift this stock higher.
Alnylam Pharmaceuticals Inc (ALNY) Q1 2019 Earnings Call Transcript
ALNY earnings call for the period ending March 31, 2019.
Is Alnylam Pharmaceuticals a Buy Now?
Everything's falling into place for the pioneer of RNA interference.
2 Biotechs With Big Dates in April
Here's what you need to know about two biotechs that will present trial results that could send their stock prices soaring -- or plummeting.
Alnylam Pharmaceuticals Is Launched and Ready for More
The biotech has launched its first drug, Onpattro, but don't forget about its pipeline of drugs to come.
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2018 Earnings Conference Call Transcript
ALNY earnings call for the period ending December 31, 2018.
3 Things Alnylam's Management Wants You to Know
The biotech gave investors reasons to cheer at the J.P. Morgan Healthcare Conference
RNAi Goes Big-Time in 2018
A first-in-kind FDA approval catapulted this treatment approach into the spotlight.
Alnylam Pharmaceuticals Launches Onpattro
Unfortunately, predicting the steepness of the launch is going to be tough.
